ADP-A2M4CD8

Overview

Overview

ADP-A2M4CD8 SPEAR T-cell therapy is our first "next-generation" therapy and is directed to MAGE-A4, a member of the MAGE family of cancer-testis antigens expressed in a number of solid tumor types. What differentiates this therapy from our ADP-A2M4 SPEAR T-cells is that these cells also express the CD8α co-receptor alongside the engineered TCR that targets MAGE-A4. Preclinical data indicate that co-expression of CD8α may broaden the immune response against solid tumors and increase anti-tumor activity by leveraging CD4+ cells into CD8+ killer or cytotoxic T‑cells while retaining their CD4+ helper function.

Our Trials

Our Trials

Cancer indications in the SURPASS Trial

Ovarian

Ovarian

Ovarian cancer begins in the ovaries, which are made up of three main kinds of cells. Each type of cell can develop into a different type of tumor.

Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, representing about 85% of lung cancers.

Head and Neck

Head and Neck

Head and neck cancers arise in the epithelium of the paranasal sinuses, nasopharynx, oropharynx, oral cavity, hypopharynx and larynx.

Gastric Cancer

Gastric Cancer

Stomach cancers, or gastric cancers, tend to develop slowly over many years.

Esophageal

Esophageal

Cancer of the esophagus starts in the inner layer (the mucosa) and grows outward (through the submucosa and the muscle layer). Since two types of cells can line the esophagus, there are two main types of esophageal cancer, squamous cell carcinoma and adenocarcinoma. Esophageal cancer is more common among men than among women.

Bladder

Bladder

Urothelial carcinoma, also known as transitional cell carcinoma (TCC), is the most common type of bladder cancer.

Esophagogastric Junction (EGJ)

Esophagogastric Junction (EGJ)

Adenocarcinomas that start at the area where the esophagus joins the stomach (the GE junction, which includes about the first two inches (5 cm) of the stomach), tend to behave like cancers in the esophagus and are treated like them, as well.

Publications

Review our findings and publications.

Latest News

We announced clinical responses across five solid tumor indications with an overall response rate of 36% and promising early durability from our next-generation SURPASS trial.

View Press Release